Fig. 1: Overview of immune checkpoint inhibitor targets in cancer immunotherapy. | npj Gut and Liver

Fig. 1: Overview of immune checkpoint inhibitor targets in cancer immunotherapy.

From: Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models

Fig. 1

This schematic illustrates various immune checkpoint inhibitors (ICIs) and their respective targets within the tumor microenvironment. ICIs include various anti-CTLA-4, anti-PD-1 targeting PD-1 receptors, and anti-PD-L1 antibodies. Magrolimab is depicted targeting CD47 to prevent the ‘don’t eat me’ signal on cancer cells, while TIGIT inhibitors interact with TIGIT receptors on T cells. Other ICIs, such as Enoblituzumab and Orlotamab, are shown to target unspecified antigens, Relatlimab binds LAG3 on T cells, and Cobolimab targets TIM3. The figure underscores the complex interplay between the immune system and cancer cells and highlights the multiplicity of potential therapeutic targets for ICIs.

Back to article page